Hypopharyngeal Neoplasms

Phase 3 trials (11)

• atezolizumab
• durvalumab
• fluorouracil
• paclitaxel
• pembrolizumab
• carboplatin
• bevacizumab
• cetuximab
• docetaxel
• cisplatin
• tislelizumab

Phase 2 trials (17)

• 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
• bmx-001
• lapatinib
• nivolumab
• ipatasertib
• nimotuzumab
• celecoxib
• capecitabine
• cabozantinib
• nedaplatin
• sodium thiosulfate
• lovastatin
• fludeoxyglucose f-18
• cemiplimab
• camrelizumab
• toripalimab
• debio 1143

Phase 1 trials (5)

• buparlisib
• Peposertib
• elimusertib
• rp-3500
• Autologous tumor vaccine

Other trials (2)

• metoclopramide
• doxepin

Organization Involved with Phase 3 Indications (1)

• Sun Yat-Sen University

Organization Involved with Phase 2 Indications (11)

• Bristol-Myers Squibb
• Biotech Pharmaceutical Co., Ltd.
• Shanghai Junshi Bioscience Co.,Ltd.
• National Cancer Institute (NCI)
• Harvard University
• Stanford University
• University of Zurich
• Peking University
• The Second People's Hospital of Sichuan
• Sungkyunkwan University
• Chinese Academy of Medical Sciences

Organization Involved with Phase 1 Indications (1)

• Novartis

Organization Involved with Other Experimental Indications (3)

• King Faisal University
• King Faisal Specialist Hospital
• China Medical University